Compounds > alanine
Page last updated: 2024-11-08

alanine and Nausea

alanine has been researched along with Nausea in 12 studies

Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.

Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.

Research Excerpts

ExcerptRelevanceReference
"Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has recently been shown to have activity as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)."9.16Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. ( Baudelet, C; Finn, RS; Kang, YK; Lim, HY; Manekas, D; Mulcahy, M; Park, JW; Polite, BN; Walters, I, 2012)
"The fatty acid amide oleoyl glycine (OlGly) and its more stable methylated form oleoyl alanine (OlAla) reduce naloxone-precipitated morphine withdrawal (MWD)-induced conditioned gaping (nausea) responses in rats."8.12Effect of oleoyl glycine and oleoyl alanine on lithium chloride induced nausea in rats and vomiting in shrews. ( Limebeer, CL; Mechoulam, R; Parker, LA; Rock, EM; Smoum, R, 2022)
"Fluvoxamine was administered for 6 weeks with a specific dosage plan (50-200 mg/day) in 66 Japanese major depressive patients."5.32Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. ( Higuchi, H; Inoue, K; Ito, K; Itoh, K; Kamata, M; Naito, S; Ohkubo, T; Sato, K; Shimizu, T; Suzuki, T; Takahashi, H; Yoshida, K, 2003)
"Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has recently been shown to have activity as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)."5.16Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. ( Baudelet, C; Finn, RS; Kang, YK; Lim, HY; Manekas, D; Mulcahy, M; Park, JW; Polite, BN; Walters, I, 2012)
"The fatty acid amide oleoyl glycine (OlGly) and its more stable methylated form oleoyl alanine (OlAla) reduce naloxone-precipitated morphine withdrawal (MWD)-induced conditioned gaping (nausea) responses in rats."4.12Effect of oleoyl glycine and oleoyl alanine on lithium chloride induced nausea in rats and vomiting in shrews. ( Limebeer, CL; Mechoulam, R; Parker, LA; Rock, EM; Smoum, R, 2022)
"Thirty patients with advanced metastatic colorectal adenocarcinoma were treated with alanosine at a dose of 160 mg/m2 daily for 5 days every 4 weeks."3.66A phase II study of alanosine in advanced large bowel carcinoma. ( Hahn, RG; Hineman, V; Moertel, CG; Rubin, J; Schutt, AJ, 1983)
"73 log10 copies per milliliter, including a dose-response relationship for viral load decrease up to 25 mg."2.78Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. ( Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L, 2013)
"Fluvoxamine was administered for 6 weeks with a specific dosage plan (50-200 mg/day) in 66 Japanese major depressive patients."1.32Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. ( Higuchi, H; Inoue, K; Ito, K; Itoh, K; Kamata, M; Naito, S; Ohkubo, T; Sato, K; Shimizu, T; Suzuki, T; Takahashi, H; Yoshida, K, 2003)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19905 (41.67)18.7374
1990's0 (0.00)18.2507
2000's2 (16.67)29.6817
2010's3 (25.00)24.3611
2020's2 (16.67)2.80

Authors

AuthorsStudies
Rock, EM1
Limebeer, CL1
Smoum, R1
Mechoulam, R1
Parker, LA1
Zekarias, A1
Watson, S1
Vidlin, SH1
Grundmark, B1
Ruane, PJ1
DeJesus, E2
Berger, D1
Markowitz, M1
Bredeek, UF1
Callebaut, C2
Zhong, L2
Ramanathan, S1
Rhee, MS1
Fordyce, MW2
Yale, K1
Sax, PE1
Wohl, D1
Yin, MT1
Post, F1
Saag, M1
Pozniak, A1
Thompson, M1
Podzamczer, D1
Molina, JM1
Oka, S1
Koenig, E1
Trottier, B1
Andrade-Villanueva, J1
Crofoot, G1
Custodio, JM1
Plummer, A1
Cao, H1
Martin, H1
Cheng, AK1
McCallister, S1
Vail, DM1
Thamm, DH1
Reiser, H1
Ray, AS1
Wolfgang, GH1
Watkins, WJ1
Babusis, D1
Henne, IN1
Hawkins, MJ1
Kurzman, ID1
Jeraj, R1
Vanderhoek, M1
Plaza, S1
Anderson, C1
Wessel, MA1
Robat, C1
Lawrence, J1
Tumas, DB1
Finn, RS1
Kang, YK1
Mulcahy, M1
Polite, BN1
Lim, HY1
Walters, I1
Baudelet, C1
Manekas, D1
Park, JW1
Yoshida, K1
Naito, S1
Takahashi, H1
Sato, K1
Ito, K1
Kamata, M1
Higuchi, H1
Shimizu, T1
Itoh, K1
Inoue, K1
Suzuki, T1
Ohkubo, T1
O'Connell, MJ1
Rubin, J2
Schutt, AJ2
Moertel, CG2
Kvols, LK1
Hineman, V1
Hahn, RG1
Stanley, RJ1
Melson, GL1
Cubillo, E1
Hesker, AE1
Wilson, WL1
Hurley, JD1
Mrazek, RG1
Vinnars, E1
Fürst, P1
Hallgren, B1
Hermansson, IL1
Josephson, B1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.[NCT03126370]Phase 410 participants (Actual)Interventional2018-01-08Completed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Trea[NCT01780506]Phase 3872 participants (Actual)Interventional2012-12-26Completed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treat[NCT01797445]Phase 3872 participants (Actual)Interventional2013-03-12Completed
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994]275 participants (Actual)Observational [Patient Registry]2018-02-06Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Week 12 Plasma Tenofovir Area Under the Plasma Concentration vs. Time Curve From Time 0 to 24 Hours (AUC0-24) at 24 and 28 Weeks

Compare plasma tenofovir AUC0-24 between TAF with boosted PI vs. TDF with boosted PI (Phase 2 vs. 1), and between TAF with boosted PI and LDV/SOF vs. TDF with boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 weeks and 28 weeks

Interventionng*h/mL (Geometric Mean)
TDF With a Boosted PI3466
TAF With a Boosted PI743
TAF With a Boosted PI and LDV/SOF868

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS)

Compare tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 and 28 weeks

Interventionfmol/2x7mm punches (Geometric Mean)
TDF With a Boosted PI36014
TAF With a Boosted PI6735
TAF With a Boosted PI and LDV/SOF6100

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs) at 24 and 28 Weeks

Compare tenofovir-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1). (NCT03126370)
Timeframe: 12 weeks, and 24 weeks and 28 weeks

Interventionfmol/10^6 cells (Geometric Mean)
TDF With a Boosted PI83.0
TAF With a Boosted PI926
TAF With a Boosted PI and LDV/SOF1129

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: eGFR

Change in estimated glomerular filtration rate (eGFR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

InterventionmL/min/1.73 m^2 (Geometric Mean)
TDF With a Boosted PI86.7
TAF With a Boosted PI91.0
TAF With a Boosted PI and LDV/SOF88.1

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: UPCR

Change in estimated glomerular filtration rate (eGFR) and renal biomarkers: Urine protein to creatinine ratio (UPCR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

Interventionmg/g (Geometric Mean)
TDF With a Boosted PI134
TAF With a Boosted PI118
TAF With a Boosted PI and LDV/SOF97.3

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: B2M/Cr Ratio, and RBP/Cr Ratio

Change in renal biomarkers: urinary beta-2 microglobulin (B2M)/creatinine (Cr) ratio, and urinary retinol binding protein (RBP)/Cr ratio (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

,,
Interventionug/g (Geometric Mean)
β2M:Cr ratioRBP:Cr ratio
TAF With a Boosted PI224242
TAF With a Boosted PI and LDV/SOF178146
TDF With a Boosted PI419436

Change From Baseline in CD4+ Cell Count at Week 144

(NCT01780506)
Timeframe: Baseline; Week 144

Interventioncells/µL (Mean)
E/C/F/TAF323
E/C/F/TDF310

Change From Baseline in CD4+ Cell Count at Week 48

(NCT01780506)
Timeframe: Baseline; Week 48

Interventioncells/µL (Mean)
E/C/F/TAF235
E/C/F/TDF221

Change From Baseline in CD4+ Cell Count at Week 96

(NCT01780506)
Timeframe: Baseline; Week 96

Interventioncells/µL (Mean)
E/C/F/TAF285
E/C/F/TDF271

Change From Baseline in Serum Creatinine at Week 144

(NCT01780506)
Timeframe: Baseline; Week 144

Interventionmg/dL (Mean)
E/C/F/TAF0.04
E/C/F/TDF0.08

Change From Baseline in Serum Creatinine at Week 48

(NCT01780506)
Timeframe: Baseline; Week 48

Interventionmg/dL (Mean)
E/C/F/TAF0.08
E/C/F/TDF0.11

Change From Baseline in Serum Creatinine at Week 96

(NCT01780506)
Timeframe: Baseline; Week 96

Interventionmg/dL (Mean)
E/C/F/TAF0.05
E/C/F/TDF0.07

Percent Change From Baseline in Hip BMD at Week 144

Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144

Interventionpercent change (Mean)
E/C/F/TAF-0.826
E/C/F/TDF-3.475

Percent Change From Baseline in Hip BMD at Week 96

Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96

Interventionpercent change (Mean)
E/C/F/TAF-0.951
E/C/F/TDF-3.515

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01780506)
Timeframe: Baseline; Week 48

Interventionpercent change (Mean)
E/C/F/TAF-0.865
E/C/F/TDF-3.200

Percent Change From Baseline in Spine BMD at Week 144

Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144

Interventionpercent change (Mean)
E/C/F/TAF-0.809
E/C/F/TDF-3.023

Percent Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 48

Interventionpercent change (Mean)
E/C/F/TAF-1.337
E/C/F/TDF-2.956

Percent Change From Baseline in Spine BMD at Week 96

Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96

Interventionpercent change (Mean)
E/C/F/TAF-0.907
E/C/F/TDF-3.053

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 144

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144

Interventionpercent change (Median)
E/C/F/TAF-24.6
E/C/F/TDF60.4

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48

Interventionpercent change (Median)
E/C/F/TAF-32.8
E/C/F/TDF18.0

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96

Interventionpercent change (Median)
E/C/F/TAF-33.5
E/C/F/TDF32.5

Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 144

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144

Interventionpercent change (Median)
E/C/F/TAF37.4
E/C/F/TDF106.9

Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96

Interventionpercent change (Median)
E/C/F/TAF11.3
E/C/F/TDF75.0

Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48

Interventionpercent change (Median)
E/C/F/TAF6.9
E/C/F/TDF51.2

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Week 48

Interventionpercentage of participants (Number)
E/C/F/TAF93.1
E/C/F/TDF92.8

Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 144

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 144 weeks

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3
E/C/F/TAF31.36.00.2
E/C/F/TDF37.17.00.2

Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 48

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 48 weeks

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3
E/C/F/TAF25.84.60
E/C/F/TDF32.34.90.2

Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 96

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 96 weeks

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3
E/C/F/TAF28.85.10.2
E/C/F/TDF33.95.80.2

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48, 96, and 144

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48, 96, and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 48, 96. and 144

,
Interventionpercentage of participants (Number)
Week 48Week 96Week 144
E/C/F/TAF86.484.484.6
E/C/F/TDF87.383.680.1

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 and 144

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Weeks 96 and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 96 and 144

,
Interventionpercentage of participants (Number)
Week 96Week 144
E/C/F/TAF89.286.9
E/C/F/TDF88.283.1

Change From Baseline in CD4+ Cell Count at Week 48

(NCT01797445)
Timeframe: Baseline; Week 48

Interventioncells/µL (Mean)
E/C/F/TAF225
E/C/F/TDF200

Change From Baseline in CD4+ Cell Count at Week 96

(NCT01797445)
Timeframe: Baseline; Week 96

Interventioncells/µL (Mean)
E/C/F/TAF274
E/C/F/TDF260

Change From Baseline in Serum Creatinine at Week 48

(NCT01797445)
Timeframe: Baseline; Week 48

Interventionmg/dL (Mean)
E/C/F/TAF0.08
E/C/F/TDF0.12

Change From Baseline in Serum Creatinine at Week 96

(NCT01797445)
Timeframe: Baseline; Week 96

Interventionmg/dL (Mean)
E/C/F/TAF0.04
E/C/F/TDF0.07

Percent Change From Baseline in Hip BMD at Week 96

Hip BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96

Interventionpercent change (Mean)
E/C/F/TAF-0.364
E/C/F/TDF-3.023

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01797445)
Timeframe: Baseline; Week 48

Interventionpercent change (Mean)
E/C/F/TAF-0.420
E/C/F/TDF-2.603

Percent Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 48

Interventionpercent change (Mean)
E/C/F/TAF-1.278
E/C/F/TDF-2.759

Percent Change From Baseline in Spine BMD at Week 96

Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96

Interventionpercent change (Mean)
E/C/F/TAF-1.017
E/C/F/TDF-2.516

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48

Interventionpercent change (Median)
E/C/F/TAF-29.3
E/C/F/TDF32.3

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96

Interventionpercent change (Median)
E/C/F/TAF-31.0
E/C/F/TDF35.2

Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96

Interventionpercent change (Median)
E/C/F/TAF16.9
E/C/F/TDF73.7

Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48

Interventionpercent change (Median)
E/C/F/TAF13.3
E/C/F/TDF51.7

Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Week 48

Interventionpercentage of participants (Number)
E/C/F/TAF91.6
E/C/F/TDF88.5

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Week 96

Interventionpercentage of participants (Number)
E/C/F/TAF84.0
E/C/F/TDF82.3

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48 and 96

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48 and 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Weeks 48 and 96

,
Interventionpercentage of participants (Number)
Week 48Week 96
E/C/F/TAF82.478.7
E/C/F/TDF80.776.8

Percentage of Participants With Treatment-emergent Proteinuria Through Week 48

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01797445)
Timeframe: Baseline to Week 48

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3
E/C/F/TAF27.34.70
E/C/F/TDF31.64.60

Percentage of Participants With Treatment-emergent Proteinuria Through Week 96

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01797445)
Timeframe: Baseline to Week 96

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3
E/C/F/TAF31.85.40
E/C/F/TDF36.95.10

Trials

5 trials available for alanine and Nausea

ArticleYear
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
    Journal of acquired immune deficiency syndromes (1999), 2013, Aug-01, Volume: 63, Issue:4

    Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Area Under Curve; Dose-Response Relationship, Drug;

2013
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-01, Volume: 18, Issue:7

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alanine; alpha-Fetoproteins; Appetite; Carcino

2012
Clinical trial of PALA and L-Alanosine in advanced colorectal carcinoma.
    Cancer treatment reports, 1983, Volume: 67, Issue:12

    Topics: Adult; Aged; Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clinical Trials

1983
A comparison of three cholecystographic agents. A double-blind study with and without a prior fatty meal.
    Radiology, 1974, Volume: 112, Issue:3

    Topics: Alanine; Butyrates; Cholecystography; Clinical Trials as Topic; Contrast Media; Diarrhea; Dietary Fa

1974

Other Studies

7 other studies available for alanine and Nausea

ArticleYear
Effect of oleoyl glycine and oleoyl alanine on lithium chloride induced nausea in rats and vomiting in shrews.
    Psychopharmacology, 2022, Volume: 239, Issue:2

    Topics: Alanine; Animals; Glycine; Lithium Chloride; Nausea; Rats; Rats, Sprague-Dawley; Shrews; Vomiting

2022
Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Drug safety, 2020, Volume: 43, Issue:12

    Topics: Abdominal Pain; Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agent

2020
Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, May-15, Volume: 15, Issue:10

    Topics: Alanine; Animals; Animals, Domestic; Anorexia; Antineoplastic Agents; Area Under Curve; Diarrhea; Di

2009
Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine.
    Neuropsychobiology, 2003, Volume: 48, Issue:1

    Topics: Adult; Aged; Alanine; Analysis of Variance; Drug Administration Schedule; Female; Fluvoxamine; Gene

2003
A phase II study of alanosine in advanced large bowel carcinoma.
    American journal of clinical oncology, 1983, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Alanine; Antibiotics, Antineoplastic; Colonic Neoplasms; Drug Evaluatio

1983
Phase II study of alanine mustard (NSC-17663).
    Cancer chemotherapy reports, 1970, Volume: 54, Issue:5

    Topics: Alanine; Blood Cell Count; Bone Marrow; Humans; Leukemia, Myeloid; Mustard Compounds; Nausea; Thromb

1970
The nutritive effect in man of non-essential amino acids infused intravenously (together with the essential ones). I. Individual non-essential amino acids.
    Acta anaesthesiologica Scandinavica, 1970, Volume: 14, Issue:3

    Topics: Adult; Alanine; Amino Acids; Ammonia; Arginine; Creatinine; Female; Glutamates; Glycine; Histidine;

1970